Although some trials of IGF-1R targeting agents have shown safety issues or limited efficacy (Table 1), it is hoped that further investigation into this strategy of combining anti-cancer drugs with agents that inhibit IGF/IGF-1R signaling will yield effective treatment for HBV-associated HCC. This evidence concerns the gene IGF1R and hepatocellular carcinoma.